Liom
Non-invasive glucose monitoring, seamlessly integrated with health metrics. The ultimate wearable.
Non-invasive glucose monitoring, seamlessly integrated with health metrics. The ultimate wearable.
Spiden is a biotechnology startup based in Switzerland, founded in 2017. The company's slogan "A revolutionary leap forward in the well-being of humanity through real-time continuous biomarker and drug monitoring" reflects its ambitious mission to improve human health and extend life expectancy.
Spiden's focus on personalized products and solutions through continuous monitoring of vital medical indicators sets it apart in the biotechnology industry. By uniquely combining state-of-the-art detection and data science techniques, the company aims to revolutionize healthcare.
Recently, Spiden secured a significant $15.00MConvertible Note investment on 01 January 2023, indicating a strong investor interest in the company's vision and potential. The investors behind this latest investment are yet to be disclosed, but it underscores the confidence in Spiden's innovative approach to biotechnology.
Moreover, the company actively engages with the community through a clinical research program for blood donation & analysis, inviting individuals to contribute to its groundbreaking research and development efforts.
Overall, Spiden presents a compelling opportunity for venture capital firms looking to invest in disruptive biotechnology ventures with the potential to redefine the future of healthcare and human well-being.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | $15.00M | - | 01 Jan 2023 | |
| Seed Round | $18.00M | 8 |
|
29 Apr 2021 |
| Seed Round | $7.25M | 1 | Daniel Gutenberg | 30 Dec 2017 |
No recent news or press coverage available for Liom.
We care about your data, and we'd love to use cookies make your experience better.
